Journal of Infectious Diseases Publishes ContraFect Corporation's Scientific Research

YONKERS, NY--(Marketwired - May 13, 2014) - ContraFect Corporation, a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, announced today that the Journal of Infectious Diseases, JID 2014:209 (1 May) has published the results of its scientific research on its lead compound, CF-301. 

The peer-reviewed journal article is titled "Combination Therapy with Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia," and highlights the synergistic nature of CF-301 with standard-of-care antibiotics, daptomycin and vancomycin. A free copy of the article can be obtained on the Company's website.

According to the authors, CF-301 is being developed to treat Staphylococcus aureus (Staph) because of its potent inhibitory activity, specificity to Staph, and rapid bacteria killing effects. As described in the article, CF-301 also demonstrates activity on antibiotic-resistant strains, has a low resistance profile, eradicates biofilms, and acts synergistically with antibiotics.

"We are pleased to present our research program to the scientific community and have the Journal of Infectious Diseases recognize the program's scientific advances," stated Dr. Michael Wittekind, ContraFect's chief scientific officer.

About ContraFect

ContraFect Corporation is a biotechnology company focused on development and commercialization of protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those used in hospital-based settings. ContraFect intends to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses. ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

Safe Harbor Statement

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with our ability to obtain additional funds, obtain and maintain all necessary patents and licenses, meet applicable regulatory standards and receive required regulatory approvals, manufacture or commercialize our products at reasonable costs and compete with other products and market our products in a profitable manner. We assume no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.